Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. QuVa Pharma, Inc.
WARNING LETTER
•QuVa Pharma, Inc.•October 14, 2022

QuVa Pharma, Inc. – FDA Warning Letter, Oct 14, 2022

Record Details

The FDA issued a Warning Letter to QuVa Pharma, Inc. (Bloomsbury, NJ) following an inspection from August 16 to October 14, 2022. The facility, registered as an outsourcing facility under FDCA section 503B, was found to have serious deficiencies in producing sterile drug products, rendering them adulterated under sections 501(a)(2)(A) (insanitary conditions) and 501(a)(2)(B) (CGMP violations) of the FDCA.

Specific deficiencies included inadequate microbial recovery action levels in ISO 5 areas, where any contamination should trigger immediate assessment of drug products. The company's updated SOP allowed for a (b)(4) CFU action level, which the FDA deemed insufficient. Additionally, investigations into incidents like ISO 5 hood pressure issues and suspected drug splash were found to be lacking or unclear, with insufficient documentation and discrepancies between reports.

The FDA acknowledged QuVa Pharma's voluntary recall of oxytocin 30 Units/500 mL (Lot # 30027403) due to incorrect formulation on September 20, 2022. While some corrective actions were noted, many lacked adequate supporting documentation or were deemed deficient. The FDA strongly recommended a comprehensive assessment of operations, including aseptic processing, with assistance from a third-party consultant. Failure to address these violations promptly may result in legal action

Company
QuVa Pharma, Inc.
Inspection date
October 14, 2022
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations I
Person
  • Lisa M. Harlan (Program Division Director)
View Company Profile

ID · 4dfc2843-4da2-4f5c-a7d2-ac6b7365a71e

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 353b21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 360eee-121 U.S.C. 353b(d)(4)21 U.S.C. 351(a)(2)(A)21 U.S.C. 331(k)21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for QuVa Pharma, Inc.
  • 483 - 2022-10-14October 14, 2022
  • 483 - 2022-08-18August 18, 2022
  • 483 - 2019-05-31May 31, 2019
  • 483 - 2019-04-23April 23, 2019
  • 483 - 2019-03-14March 14, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore QuVa Pharma, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.